Word: last
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
...that very skin. Yet increasingly they do. Tattooing and piercing, once the preference of biker chicks and sailors on shore leave, are attracting ever younger recruits. Chances are that someday soon your 12-year-old--the same kid who cried real tears over getting a booster shot at her last annual checkup--will be bugging you for a naval piercing or a tattoo of James Van Der Beek's face on her midriff...
...wise Aaron clearly can't imagine any drawbacks to his future as a 40-year-old man with a Yoda tattoo.) Ron Stiehl, the proprietor of my local piercing and tattoo parlor, says that for kids who want to try out a tattoo, artists can apply henna designs, which last about three weeks...
...phone-bank virtuoso who does projects for George W. Bush. And there's evidence of Microsoft's courting business and political players at the smallest levels. In September, senior vice president Craig Mundie spoke to the Cedar Rapids, Iowa, Chamber of Commerce, drawing an overflow crowd of about 900. Last month former Republican National Committee chairman Haley Barbour, who has been helping Microsoft court Republican Governors, spoke to the Hartford [Conn.] Area Business Economists Association about the case; turnout was extremely light...
...course, Schering-Plough would pay almost any amount of money to protect its exclusive right to sell Claritin, a drug that brings it more than $5 million in revenue a day. Claritin sales totaled $1.9 billion last year, and will balloon to $4 billion by 2002, according to a market analyst. To keep the money coming in, the company doubled its lobbying outlay starting in 1996 to more than $4 million in 1998. Among its other paid advocates: former Senator Dennis DeConcini; former Watergate assistant special prosecutor Richard Ben-Veniste; and Thomas Parry, former chief of staff for Senator Orrin...
Patent extensions for drugs are rare. The last one, granted in 1996, was for the popular arthritis drug Daypro. So Schering-Plough has tried to work the system every way it can. First it wanted Congress to approve a straight extension of its patent. When that didn't fly, it tried a bill that would have shifted any patent-extension decision away from Congress to a new review board at the Patent and Trademark Office, and defined criteria for such extensions in ways that tended to favor the drug companies. But that bill, quietly introduced by New Jersey Senator Frank...